Outcomes Across Nonmelanoma Skin Cancer Treatments Similar
Brachytherapy and Mohs micrographic surgery show better cosmetic results
Conclusions: CT-based surface mould brachytherapy results in better conformity of superficial lesions on small, irregular surfaces such as the nose and inner canthus than electrons with a slightly higher skin dose. PMID: 31969913 [PubMed]
Brachytherapy alternative to Mohs surgery in early - stage nonmelanoma skin cancers of head, neck
Lower sales of its robotic intraoperative radiation therapy system adversely...Read more on AuntMinnie.comRelated Reading: Sensus scores Premier contract for brachytherapy Sensus inks R&D pact with UPenn Sensus touts research for nonmelanoma skin cancer FDA clears Sensus Healthcare's IORT system Sensus names new VP of clinical development
Non-melanoma skin cancer (NMSC) represents the most frequently diagnosed malignancy worldwide, most being cutaneous basal cell and squamous cell carcinoma. The global incidence of NMSC continues to increase as the global population ages. Numerous treatment options are available for NMSC patients, with radiotherapy an efficacious and tissue-preserving non-surgical option. External beam radiotherapy and brachytherapy are modalities with specific indications and advantages in treating NMSC. Where excision is not an option (medically/technically inoperable) or considered less ideal (e.g.
Surgery, Doylestown, PA
AbstractPurpose of ReviewThe incidence of non-melanomatous skin cancer (NMSC) increases with age and there are specific considerations regarding management of NMSC for the older patient population. Here we will review current data regarding treatment considerations and options for older patients with NMSC.Recent FindingsHypofractionated regimens and high-dose brachytherapy may be non-surgical treatment options for older patients with NMSC. Other less aggressive strategies such as active surveillance can also be considered in some settings.SummaryManagement of NMSC in the older patient population requires a thorough assessm...
Superficial radiation therapy provider Sensus Healthcare has signed a group...Read more on AuntMinnie.comRelated Reading: Sensus inks R&D pact with UPenn Sensus touts research for nonmelanoma skin cancer FDA clears Sensus Healthcare's IORT system Sensus names new VP of clinical development Sensus appoints new sales VP for oncology
We present our Institution experience employing different techniques of Brachytherapy for this scenario.
Surgery is a standard treatment for patients suffering from non-melanoma skin cancer. However, postoperative relapse or positive margins after surgery are linked with worse outcome. We aimed to analyze surface high-dose-rate brachytherapy as an adjuvant/salvage option.
Skin cancer is the most common form of cancer in the United States. Research estimates that nonmelanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million Americans a year. The incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades. Fortunately, most NMSC lesions are detected at an early stage that is amenable to very effective local therapy and thus are highly curable. Various therapeutic modalities are currently being used to treat these tumors, including surgery, topical treatments and radiotherapy.